Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth

Chemistry and Biology

Volumn 20, Issue 11, 2013, Pages 1329-1339

  Garapaty Rao, Shivani ^a   Nasveschuk, Christopher ^a   Gagnon, Alexandre ^a,b   Chan, Eric Y ^a   Sandy, Peter ^a   Busby, Jennifer ^a   Balasubramanian, Srividya ^a   Campbell, Robert ^a   Zhao, Feng ^a   Bergeron, Louise ^a   Audia, James E ^a   Albrecht, Brian K ^a   Harmange, Jean Christophe ^a   Cummings, Richard ^a   Trojer, Patrick ^a  

^a Department of Structural Biology   (United States)

^b UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EZH1 SMALL MOLECULE INHIBITOR; EZH2 SMALL MOLECULE INHIBITOR; HISTONE H3; HISTONE H3K27 PROTEIN; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN INHIBITOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EZH1; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EZH1 PROTEIN, HUMAN; EZH2 PROTEIN, HUMAN; MOLECULAR LIBRARY;

ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SELECTIVITY; FEMALE; GENE EXPRESSION; HISTONE METHYLATION; HUMAN; HUMAN CELL; IC 50; LARGE CELL LYMPHOMA; LYMPHOMA CELL; MALE; MISSENSE MUTATION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; WILD TYPE; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; HELA CELL LINE; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; MOLECULAR LIBRARY; PATHOLOGY; PHARMACOLOGY; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HELA CELLS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MOLECULAR STRUCTURE; POLYCOMB REPRESSIVE COMPLEX 2; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 84888303259     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2013.09.013     Document Type: Article

References (42)

1. B.D. Bennett, E.H. Kimball, M. Gao, R. Osterhout, S.J. Van Dien, and J.D. Rabinowitz Absolute metabolite concentrations and implied enzyme active site occupancy in Escherichia coli Nat. Chem. Biol. 5 2009 593 599
2. R.J. Bryant, N.A. Cross, C.L. Eaton, F.C. Hamdy, and V.T. Cunliffe EZH2 promotes proliferation and invasiveness of prostate cancer cells Prostate 67 2007 547 556
3. R.J. Bryant, S.J. Winder, S.S. Cross, F.C. Hamdy, and V.T. Cunliffe The Polycomb Group protein EZH2 regulates actin polymerization in human prostate cancer cells Prostate 68 2008 255 263
4. H. Chen, S.W. Tu, and J.T. Hsieh Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer J. Biol. Chem. 280 2005 22437 22444
5. Y. Cheng, and W.H. Prusoff Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 22 1973 3099 3108
6. R.A. Copeland Mechanistic considerations in high-throughput screening Anal. Biochem. 320 2003 1 12
7. E. Diaz, C.A. Machutta, S. Chen, Y. Jiang, C. Nixon, G. Hofmann, D. Key, S. Sweitzer, M. Patel, and Z. Wu Development and validation of reagents and assays for EZH2 peptide and nucleosome high-throughput screens J. Biomol. Screen. 17 2012 1279 1292
8. P.A. DiMaggio Jr., N.L. Young, R.C. Baliban, B.A. Garcia, and C.A. Floudas A mixed integer linear optimization framework for the identification and quantification of targeted post-translational modifications of highly modified proteins using multiplexed electron transfer dissociation tandem mass spectrometry Mol. Cell. Proteomics 8 2009 2527 2543
9. A.D. Ferguson, N.A. Larsen, T. Howard, H. Pollard, I. Green, C. Grande, T. Cheung, R. Garcia-Arenas, S. Cowen, and J. Wu Structural basis of substrate methylation and inhibition of SMYD2 Structure 19 2011 1262 1273
10. N.J. Francis, M. Rowlands, P. Workman, K. Jones, and W. Aherne Small-molecule inhibitors of the protein methyltransferase SET7/9 identified in a high-throughput screen J. Biomol. Screen. 17 2012 1102 1109
11. B.A. Garcia, S. Mollah, B.M. Ueberheide, S.A. Busby, T.L. Muratore, J. Shabanowitz, and D.F. Hunt Chemical derivatization of histones for facilitated analysis by mass spectrometry Nat. Protoc. 2 2007 933 938
12. K.H. Hansen, A.P. Bracken, D. Pasini, N. Dietrich, S.S. Gehani, A. Monrad, J. Rappsilber, M. Lerdrup, and K. Helin A model for transmission of the H3K27me3 epigenetic mark Nat. Cell Biol. 10 2008 1291 1300
13. B.D. Karanikolas, M.L. Figueiredo, and L. Wu Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines Prostate 70 2010 675 688
14. C.G. Kleer, Q. Cao, S. Varambally, R. Shen, I. Ota, S.A. Tomlins, D. Ghosh, R.G. Sewalt, A.P. Otte, and D.F. Hayes EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells Proc. Natl. Acad. Sci. USA 100 2003 11606 11611
15. S.K. Knutson, T.J. Wigle, N.M. Warholic, C.J. Sneeringer, C.J. Allain, C.R. Klaus, J.D. Sacks, A. Raimondi, C.R. Majer, and J. Song A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells Nat. Chem. Biol. 8 2012 890 896
16. K.D. Konze, A. Ma, F. Li, D. Barsyte-Lovejoy, T. Parton, C.J. Macnevin, F. Liu, C. Gao, X.P. Huang, and E. Kuznetsova An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1 ACS Chem. Biol. 8 2013 1324 1334
17. S. Kubicek, R.J. O'Sullivan, E.M. August, E.R. Hickey, Q. Zhang, M.L. Teodoro, S. Rea, K. Mechtler, J.A. Kowalski, and C.A. Homon Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase Mol. Cell 25 2007 473 481
18. G. Li, R. Margueron, M. Ku, P. Chambon, B.E. Bernstein, and D. Reinberg Jarid2 and PRC2, partners in regulating gene expression Genes Dev. 24 2010 368 380
19. C.R. Majer, L. Jin, M.P. Scott, S.K. Knutson, K.W. Kuntz, H. Keilhack, J.J. Smith, M.P. Moyer, V.M. Richon, R.A. Copeland, and T.J. Wigle A687V EZH2 is a gain-of-function mutation found in lymphoma patients FEBS Lett. 586 2012 3448 3451
20. R. Margueron, and D. Reinberg The Polycomb complex PRC2 and its mark in life Nature 469 2011 343 349
21. R. Margueron, G. Li, K. Sarma, A. Blais, J. Zavadil, C.L. Woodcock, B.D. Dynlacht, and D. Reinberg Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms Mol. Cell 32 2008 503 518
22. R. Margueron, N. Justin, K. Ohno, M.L. Sharpe, J. Son, W.J. Drury 3rd, P. Voigt, S.R. Martin, W.R. Taylor, and V. De Marco Role of the polycomb protein EED in the propagation of repressive histone marks Nature 461 2009 762 767
23. M.T. McCabe, A.P. Graves, G. Ganji, E. Diaz, W.S. Halsey, Y. Jiang, K.N. Smitheman, H.M. Ott, M.B. Pappalardi, and K.E. Allen Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27) Proc. Natl. Acad. Sci. USA 109 2012 2989 2994
24. M.T. McCabe, H.M. Ott, G. Ganji, S. Korenchuk, C. Thompson, G.S. Van Aller, Y. Liu, A.P. Graves, A.D. Iii, and E. Diaz EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations Nature 492 2012 108 112
25. J. Min, A. Zaslavsky, G. Fedele, S.K. McLaughlin, E.E. Reczek, T. De Raedt, I. Guney, D.E. Strochlic, L.E. Macconaill, and R. Beroukhim An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB Nat. Med. 16 2010 286 294
26. N.D. Montgomery, D. Yee, A. Chen, S. Kalantry, S.J. Chamberlain, A.P. Otte, and T. Magnuson The murine polycomb group protein Eed is required for global histone H3 lysine-27 methylation Curr. Biol. 15 2005 942 947
27. D. Pasini, A.P. Bracken, M.R. Jensen, E. Lazzerini Denchi, and K. Helin Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity EMBO J. 23 2004 4061 4071
28. D. Pasini, P.A. Cloos, J. Walfridsson, L. Olsson, J.P. Bukowski, J.V. Johansen, M. Bak, N. Tommerup, J. Rappsilber, and K. Helin JARID2 regulates binding of the Polycomb repressive complex 2 to target genes in ES cells Nature 464 2010 306 310
29. J.C. Peng, A. Valouev, T. Swigut, J. Zhang, Y. Zhao, A. Sidow, and J. Wysocka Jarid2/Jumonji coordinates control of PRC2 enzymatic activity and target gene occupancy in pluripotent cells Cell 139 2009 1290 1302
30. M.D. Plazas-Mayorca, B.M. Zee, N.L. Young, I.M. Fingerman, G. LeRoy, S.D. Briggs, and B.A. Garcia One-pot shotgun quantitative mass spectrometry characterization of histones J. Proteome Res. 8 2009 5367 5374
31. W. Qi, H. Chan, L. Teng, L. Li, S. Chuai, R. Zhang, J. Zeng, M. Li, H. Fan, and Y. Lin Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation Proc. Natl. Acad. Sci. USA 109 2012 21360 21365
32. J. Rappsilber, M. Mann, and Y. Ishihama Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips Nat. Protoc. 2 2007 1896 1906
33. B.K. Shoichet Interpreting steep dose-response curves in early inhibitor discovery J. Med. Chem. 49 2006 7274 7277
34. C.J. Sneeringer, M.P. Scott, K.W. Kuntz, S.K. Knutson, R.M. Pollock, V.M. Richon, and R.A. Copeland Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas Proc. Natl. Acad. Sci. USA 107 2010 20980 20985
35. S.L. Squazzo, H. O'Geen, V.M. Komashko, S.R. Krig, V.X. Jin, S.W. Jang, R. Margueron, D. Reinberg, R. Green, and P.J. Farnham Suz12 binds to silenced regions of the genome in a cell-type-specific manner Genome Res. 16 2006 890 900
36. J. van der Vlag, and A.P. Otte Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation Nat. Genet. 23 1999 474 478
37. S. Varambally, S.M. Dhanasekaran, M. Zhou, T.R. Barrette, C. Kumar-Sinha, M.G. Sanda, D. Ghosh, K.J. Pienta, R.G. Sewalt, and A.P. Otte The polycomb group protein EZH2 is involved in progression of prostate cancer Nature 419 2002 624 629
38. T.J. Wigle, S.K. Knutson, L. Jin, K.W. Kuntz, R.M. Pollock, V.M. Richon, R.A. Copeland, and M.P. Scott The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states FEBS Lett. 585 2011 3011 3014
39. K. Xu, Z.J. Wu, A.C. Groner, H.H. He, C. Cai, R.T. Lis, X. Wu, E.C. Stack, M. Loda, and T. Liu EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent Science 338 2012 1465 1469
40. D.B. Yap, J. Chu, T. Berg, M. Schapira, S.W. Cheng, A. Moradian, R.D. Morin, A.J. Mungall, B. Meissner, and M. Boyle Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation Blood 117 2011 2451 2459
41. J. Yu, Q. Cao, J. Yu, L. Wu, A. Dallol, J. Li, G. Chen, C. Grasso, X. Cao, and R.J. Lonigro The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer Oncogene 29 2010 5370 5380
42. Y. Zheng, S.M. Sweet, R. Popovic, E. Martinez-Garcia, J.D. Tipton, P.M. Thomas, J.D. Licht, and N.L. Kelleher Total kinetic analysis reveals how combinatorial methylation patterns are established on lysines 27 and 36 of histone H3 Proc. Natl. Acad. Sci. USA 109 2012 13549 13554